PYPD

6.1206.56%
YB

Yechezkel Barenholz

Independent Non-Employee Director

Prof. Dr. Yechezkel Barenholz, Ph.D., also known as Chezy, is Chairman of Scientific Advisory Board of InnoCan Pharma Corporation. Dr. Barenholz serves as Member of Advisory Board at RedHill Biopharma Ltd. Dr. Barenholz served as Member of Scientific Advisory Board at Revium Rx (formerly known as Revium Rx. (formerly known as Revium Recovery Inc.)). Dr. Barenholz serves as He has been Professor of Biochemistry at the Hebrew University-Hadassah Medical School since 1982 and serves as its Head of the Department of Biochemistry. In 1998, Dr. Barenholz became the first incumbent of the Daniel G. Miller Chair in Cancer Research. He is also a Visiting Professor at the University of Virginia. He was a Donders Chair Professor at the University of Utrecht in the Netherlands in 1992 and a visiting Professor at Kyoto University, Japan. Dr. Barenholz served as a Doctoral Advisor at Elijah Bolotin. He serves as a Member of Scientific Advisory Board at Anchiano Therapeutics Ltd (formerly known as BioCancell Ltd.) (formerly, Anchiano Therapeutics Ltd.) and Idea AG. He served as an External Director at Can-Fite BioPharma Ltd. since December 2005. His interests are in basic and applied science. Dr. Barenholz is one of the leading researchers in the field of using liposome products in medicine. In basic research, Dr. Barenholz is involved in many fields related to the biochemistry and biophysics of lipids and membranes, including synthesis, chemical and physical characterization and the relationship between membrane lipid composition, structure and function. Dr. Barenholz is one of the key inventors of DOXIL, marketed by Johnson & Johnson as a cancer treatment. Dr. Barenholz is the author of over 300 publications, the editor of two special issues of Chemistry and Physics of Lipids, the Journal of Liposome Research, Cellular & Molecular Biology Letters and International Journal of Oncology. He is the author of several hundred scientific articles in liposome and related fields and has edited several scientific books Barenholz is founder of several prominent startup companies, including; Ayana Pharma Ltd that under his guidance achieved FDA approval of one of the 4 versions of FDA approved generic Doxil, now sold in the U.S. as well as the clinical stage Moebius Medical Ltd. He is Co-author of four volumes of Handbook of Nonmedical Applications of Liposomes. He is a Independent Non-Employee Director of PolyPid Ltd since April 2008. He is the co-inventor of over 25 worldwide-approved patents and the recipient of the Kay Award for innovation, the Alec D. Bangham Achievement Award and the TEVA Founders Prize. He received his Undergraduate, M.Sc. and Ph.D. degrees in Biochemistry from the Hebrew University of Jerusalem.

Positions